Decoy Therapeutics is trading at $4.12 (+10.03%) after announcing that its D-MAV candidate showed in vitro activity against the wild-type Ebola Zaire virus.
- The results validate the D-MAV platform beyond coronaviruses, which the company identifies as a clear company-specific catalyst.
- The move appears driven by the Ebola update rather than sector sentiment, as broader biotech shares are currently trading lower.